GlassScriptPhysician profile
Ama A Amofa
NPI 1861167082
$4,107.11
in general payments reported to CMS, 2019-2025
15 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $123 · 2022: $55.63 · 2023: $1,782 · 2024: $1,934 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,856 · Education: $72.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,855.50 |
| Education | $72.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $680.49 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $679.11 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $557.84 | 2023-2024 | Caplyta |
| Abbvie INC. | $460.39 | 2023-2025 | |
| Alkermes, INC. | $368.21 | 2021-2025 | Vivitrol, Vivitrol |
| Janssen Pharmaceuticals, INC | $322.41 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $255.50 | 2023 | Auvelity |
| Braeburn INC. | $232.68 | 2023-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $209.11 | 2024 | Fanapt |
| Lundbeck LLC | $124.46 | 2024-2025 | Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $102.48 | 2024 | |
| Indivior INC. | $54.47 | 2024 | Sublocade |
| Gilead Sciences, INC. | $32.92 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $16.31 | 2022 | |
| Corium, LLC | $10.73 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ama Amofa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.